An overview of cancer multidrug resistance: A still unsolved problem

Cellular and Molecular Life Sciences

Volumn 65, Issue 20, 2008, Pages 3145-3167

  Lage, H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

ABC transporters; Cancer; Chemotherapy; Death pathways; Drug resistance; Repair pathways; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; AZIDOPINE; CAMPTOTHECIN; CISPLATIN; COLCHICINE; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DAUNORUBICIN; DIGOXIN; DOXORUBICIN; EMETINE; EPIPODOPHYLLOTOXIN DERIVATIVE; ESTRAMUSTINE; ETOPOSIDE; FLUOROURACIL; IMATINIB; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NIFEDIPINE; PACLITAXEL; PUROMYCIN; TENIPOSIDE; TOPOTECAN; UNINDEXED DRUG; VALINOMYCIN; VERAPAMIL; VINBLASTINE; VINCRISTINE; VINDESINE;

APOPTOSIS; CANCER CELL; CANCER STEM CELL; CELL FUNCTION; DNA REPAIR; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DNA REPAIR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASTIC STEM CELLS;

EID: 53849096994     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-008-8111-5     Document Type: Review

References (222)

1. Biedler, J. L. and Riehm, H. (1970) Cellular resistance to actinomycin D in Chinese hamster cells in vitro: crossresistance, radioautographic, and cytogenetic studies. Cancer Res. 30, 1174-1184.
2. Gottesman, M. M., Fojo, T. and Bates, S. E. (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48-58.
3. Lage, H. (2003) ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int. J. Antimicrob. Agents. 22, 188-199.
4. Gottesman, M. M. and Ling, V. (2006) The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett. 580, 998-1009.
5. Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C. and Gottesman, M. M. (2006) Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219-234.
6. Kessel, D., Botterill, V. and Wodinsky, I. (1968) Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response. Cancer Res. 28, 938-941.
7. Burchenal, J. H., Robinson, E., Johnston, S. F. and Kushida, M. N. (1950) The induction of resistance to 4-amino-N10-methylpteroylglutamic acid in a strain of transmitted mouse leukemia. Science 111, 116.
8. Juliano, R. L. and Ling, V. (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455, 152-162.
9. Litman, T., Druley, T. E., Stein, W. D. and Bates SE. (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell. Mol. Life Sci. 58, 931-959.
10. Riordan, J. R. and Ling, V. (1979) Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J. Biol. Chem. 254, 12701-12705.
11. Shen, D. W., Fojo, A., Chin, J. E., Roninson, I. B., Richert, N., Pastan, I. and Gottesman, M. M. (1986) Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science 232, 643-645.
12. Kartner, N., Riordan, J. R. and Ling, V. (1983) Cell surface Pglycoprotein associated with multidrug resistance in mammalian cell lines. Science 221, 1285-1288.
13. Kartner, N., Evernden-Porelle, D., Bradley, G., and Ling, V. (1985) Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316, 820-823.
14. Surowiak, P., Materna, V., Kaplenko, I., Spaczynski, M., Dolinska-Krajewska, B., Gebarowska, E., Dietel, M., Zabel, M. and Lage, H. (2006) ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clin. Cancer Res. 12, 7149-7158.
15. Dietel, M., Arps, H., Lage, H. and Niendorf, A. (1990) Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res. 50, 6100-6106.
16. Higgins, C. F. (1992) ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol. 8, 67-113.
17. Walker, J. E., Saraste, M., Runswick, M. J. and Gay, N. J. (1982) Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J. 1, 945-951.
18. Hyde, S. C., Emsley, P., Hartshorn, M. J., Mimmack, M. M., Gileadi, U., Pearce, S. R., Gallagher, M. P., Gill, D. R., Hubbard, R. E. and Higgins, C. F. (1990) Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 346, 362-365.
19. Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., Doyle, M., FitzHugh, W., Funke, R., Gage, D. et al.; International Human Genome Sequencing Consortium. (2001) Initial sequencing and analysis of the human genome. Nature 409, 860-921.
20. Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., Gocayne, J. D., Amanatides, P., Ballew et al. (2001) The sequence of the human genome. Science 291, 1304-1351.
21. Dean, M., Rzhetsky, A. and Allikmets, R. (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11, 1156-1166.
22. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I. and Willingham, M. C. (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84, 7735-7738.
23. Cordon-Cardo, C., O Brien, J. P., Boccia, J., Casals, D., Bertino, J. R. and Melamed, M. R. (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 38, 1277-1287.
24. Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M. and Pastan, I. (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. USA 84, 265-269.
25. Goldstein, L. J., Galski, H., Fojo, A., Willingham, M., Lai, S. L., Gazdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G. M., Lieber, M., Cossman, J., Gottesman, M. M. and Pastan, I. (1989) Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst. 81, 116-124.
26. Chan, H. S., Thorner, P. S., Haddad, G. and Ling V. (1990) Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J. Clin. Oncol. 8, 689-704.
27. Chan, H. S., Haddad, G., Thorner, P. S., DeBoer, G., Lin, Y. P., Ondrusek, N., Yeger, H. and Ling, V. (1991) Pglycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N. Engl. J. Med. 325, 1608-1614.
28. Pirker, R., Wallner, J., Geissler, K., Linkesch, W., Haas, O. A., Bettelheim, P., Hopfner, M., Scherrer, R., Valent, P., Havelec, L., Ludwig, H. and Lechner, K. (1991) MDR1 gene expression and treatment outcome in acute myeloid leukemia. J. Natl. Cancer Inst. 83, 708-712.
29. Verrelle, P., Meissonnier, F., Fonck, Y., Feillel, V., Dionet, C., Kwiatkowski, F., Plagne, R. and Chassagne, J. (1991) Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J. Natl. Cancer Inst. 83, 111-116.
30. Arceci, R. J. (1993) Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 81, 2215-2222.
31. Baldini, N., Scotlandi, K., Barbanti-Bròdano, G., Manara, M. C., Maurici, D., Bacci, G., Bertoni, F., Picci, P., Sottili, S., Campanacci, M. and Serra, M. (1995) Expression of Pglycoprotein in high-grade osteosarcomas in relation to clinical outcome. N. Engl. J. Med. 333, 1380-1385.
32. Cole, S. P., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. and Deeley, R. G. (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258, 1650-1654.
33. Haimeur, A., Conseil, G., Deeley, R. G. and Cole S. P. (2004) The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr. Drug Metab. 5, 21-53.
34. Jedlitschky, G., Leier, I., Buchholz, U., Barnouin, K., Kurz, G. and Keppler, D. (1996) Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 56, 988-994.
35. Nooter, K., Brutel de la Riviere, G., Look, M. P., van Wingerden, K. E., Henzen-Logmans, S. C., Scheper, R. J., Flens, M. J., Klijn, J. G., Stoter, G. and Foekens, J. A. (1997) The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br. J. Cancer 76, 486-493.
36. Arts, H. J., Katsaros, D., de Vries, E. G., Massobrio, M., Genta, F., Danese, S., Arisio, R., Scheper, R. J., Kool, M., Scheffer, G. L., Willemse, P. H., van der Zee, A. G. and Suurmeijer, A. J. (1999) Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin. Cancer Res. 5, 2798-2805.
37. Taniguchi, K., Wada, M., Kohno, K., Nakamura, T., Kawabe, T., Kawakami, M., Kagotani, K., Okumura, K., Akiyama, S. and Kuwano, M. (1996) A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 56, 4124-4129.
38. Materna, V., Liedert, B., Thomale, J. and Lage, H. (2005) Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells. Int. J. Cancer 115, 393-402.
39. Burger, H., Foekens, J. A., Look, M. P., Meijer-van Gelder, M. E., Klijn, J. G., Wiemer, E. A., Stoter, G. and Nooter, K. (2003) RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin. Cancer Res. 9, 827-836.
40. Materna, V., Pleger, J., Hoffmann, U. and Lage, H. (2004) RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol. Oncol. 94, 152-160
41. Borst, P., de Wolf, C. and van de Wetering, K. (2007) Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 453, 661-673.
42. König, J., Rost, D., Cui, Y. and Keppler, D. (1999) Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 29, 1156-1163.
43. Scheffer, G. L., Kool, M., de Haas, M., de Vree, J. M. L., Pijnenborg, A. C. L. M., Bosman, D. K., Elferink, R. P. J. O., van der Valk, P., Borst, P. and Scheper, R. J. (2002) Tissue distribution and induction of human multidrug resistant protein 3. Lab. Invest. 82, 193-201.
44. Ohishi, Y., Oda, Y., Uchiumi, T., Kobayashi, H., Hirakawa, T., Miyamoto, S., Kinukawa, N., Nakano, H., Kuwano, M. and Tsuneyoshi, M. (2002) ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin. Cancer Res. 8, 3767-3775.
45. Faneyte, I. F., Kristel, P. M. and van de Vijver, M. J. (2004) Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. Anticancer Res. 24, 2931-2939.
46. König, J., Hartel, M., Nies, A. T., Martignoni, M. E., Guo, J., Büchler, M. W., Friess, H. and Keppler D. (2005) Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int. J. Cancer 115, 359-367.
47. Calatozzolo, C., Gelati, M., Ciusani, E., Sciacca, F. L., Pollo, B., Cajola, L., Marras, C., Silvani, A., Vitellaro-Zuccarello, L., Croci, D., Boiardi, A. and Salmaggi, A. (2005) Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J. Neurooncol. 74, 113-121.
48. Kruh, G. D., Guo, Y., Hopper-Borge, E., Belinsky, M. G. and Chen, Z. S. (2007) ABCC10, ABCC11, and ABCC12. Pflugers Arch. 453, 675-684.
49. Oguri, T., Bessho, Y., Achiwa, H., Ozasa, H., Maeno, K., Maeda, H., Sato, S. and Ueda R. (2007) MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol. Cancer Ther. 6, 122-127.
50. Kruh, G. D. and Belinsky, M. G. (2003) The MRP family of drug efflux pumps. Oncogene 22, 7537-7552.
51. Nies, A. T., Spring, H., Thon, W. F., Keppler, D. and Jedlitschky, G. (2002) Immunolocalization of multidrug resistance protein 5 in the human genitourinary system. J. Urol. 167, 2271-2275.
52. Belinsky, M. G., Chen, Z. S., Shchaveleva, I., Zeng, H. and Kruh, G. D. (2002) Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 62, 6172-6177.
53. Le Saux, O., Urban, Z., Tschuch, C., Csiszar, K., Bacchelli, B., Quaglino, D., Pasquali-Ronchetti, I., Pope, F. M., Richards, A., Terry, S., Bercovitch, L., de Paepe, A. and Boyd, C. D. (2000) Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nature Genet. 25, 223-227.
54. Matsuzaki, Y., Nakano, A., Jiang, Q. J., Pulkkinen, L. and Uitto, J. (2005) Tissue-specific expression of the ABCC6 gene. J. Invest. Dermatol. 125, 900-905.
55. Scheffer, G. L., Hu, X., Pijnenborg, A. C., Wijnholds, J., Bergen, A. A. and Scheper, R. J. (2002) MRP6 (ABCC6) detection in normal human tissues and tumors. Lab. Invest. 82, 515-518.
56. Hopper-Borge, E., Chen, Z. S., Shchaveleva, I., Belinsky, M. G. and Kruh, G. D. (2004) Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res. 64, 4927-4930.
57. Takayanagi, S., Kataoka, T., Ohara, O., Oishi, M., Kuo, M. T. and Ishikawa T. (2004) Human ATP-binding cassette transporter ABCC10: expression profile and p53-dependent upregulation. J. Exp. Ther. Oncol. 4, 239-246.
58. Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K. and Ross, D. D. (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 95, 15665-15670.
59. Allikmets, R., Schriml, L. M., Hutchinson, A., Romano-Spica, V. and Dean, M. (1998) A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58, 5337-5339.
60. Miyake, K., Mickley, L., Litman, T., Zhan, Z., Robey, R., Cristensen, B., Brangi, M., Greenberger, L., Dean, M., Fojo, T. and Bates, S. E. (1999) Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 59, 8-13.
61. Lage, H. and Dietel, M. (2000) Effect of the breast-cancer resistance protein on atypical multidrug resistance. Lancet Oncol. 1, 169-175.
62. Maliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C., Schinkel, A. H., van De Vijver, M. J., Scheper, R. J. and Schellens, J. H. (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61, 3458-3464.
63. Fetsch, P. A,, Abati, A., Litman, T., Morisaki, K., Honjo, Y., Mittal, K. and Bates, S. E. (2006) Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett. 235, 84-92.
64. Jonker, J. W., Merino, G., Musters, S., van Herwaarden, A. E., Bolscher, E., Wagenaar, E., Mesman, E., Dale, T. C. and Schinkel, A. H. (2005) The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat. Med. 11, 127-129.
65. Ross, D. D., Yang, W., Abruzzo, L. V., Dalton, W. S., Schneider, E., Lage, H., Dietel, M., Greenberger, L., Cole, S. P. and Doyle, L. A. (1999) Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Natl. Cancer Inst. 91, 429-433.
66. Ross, D. D., Karp, J. E., Chen, T. T. and Doyle, L. A. (2000) Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 96, 365-368.
67. Galimberti, S., Guerrini, F., Palumbo, G. A., Consoli, U., Fazzi, R., Morabito, F., Santini, V. and Petrini, M. (2004) Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients. Leuk. Res. 28, 367-372.
68. van der Kolk, D. M., Vellenga, E., Scheffer, G. L., Müller, M., Bates, S. E., Scheper, R. J. and de Vries E. G. (2002) Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood 99, 3763-3770.
69. Abbott, B. L., Colapietro, A. M., Barnes, Y., Marini, F., Andreeff, M. and Sorrentino, B. P. (2002) Low levels of ABCG2 expression in adult AML blast samples. Blood 100, 4594-4601.
70. van der Pol, M. A., Broxterman, H. J., Pater, J. M., Feller, N., van der Maas, M., Weijers, G. W., Scheffer, G. L., Allen, J. D., Scheper, R. J., van Loevezijn, A., Ossenkoppele, G. J. and Schuurhuis, G. J. (2003) Function of the ABC transporters, Pglycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia. Haematologica 88, 134-147.
71. Steinbach, D., Sell, W., Voigt, A., Hermann, J., Zintl, F. and Sauerbrey, A. (2002) BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16, 1443-1447.
72. Sauerbrey, A., Sell, W., Steinbach, D., Voigt, A. and Zintl, F. (2002) Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia. Br. J. Haematol. 118, 147-150.
73. Diestra, J. E., Scheffer, G. L., Català, I., Maliepaard, M., Schellens, J. H., Scheper, R. J., Germà-Lluch, J. R. and Izquierdo, M. A. (2002) Frequent expression of the multidrug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J. Pathol. 198, 213-219.
74. Kanzaki, A., Toi, M., Nakayama, K., Bando, H., Mutoh, M., Uchida, T., Fukumoto, M. and Takebayashi, Y. (2001) Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn. J. Cancer Res. 92, 452-458.
75. Faneyte, I. F., Kristel, P. M., Maliepaard, M., Scheffer, G. L., Scheper, R. J., Schellens, J. H. and van de Vijver, M. J. (2002) Expression of the breast cancer resistance protein in breast cancer. Clin. Cancer Res. 8, 1068-1074.
76. Laing, N. M., Belinsky, M. G., Kruh, G. D., Bell, D. W., Boyd, J. T., Barone, L., Testa, J. R. and Tew K. D. (1998) Amplification of the ATP-binding cassette 2 transporter gene is functionally linked with enhanced efflux of estramustine in ovarian carcinoma cells. Cancer Res. 58, 1332-1337.
77. Steinbach, D., Gillet, J. P., Sauerbrey, A., Gruhn, B., Dawczynski, K., Bertholet, V., de Longueville, F., Zintl, F., Remacle, J. and Efferth, T. (2006) ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clin. Cancer Res. 12, 4357-4363.
78. Izquierdo, M. A., Neefjes, J. J., Mathari, A. E., Flens, M. J., Scheffer, G. L. and Scheper, R. J. (1996) Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines. Br. J. Cancer 74, 1961-1967.
79. Lage, H., Perlitz, C., Abele, R., Tampé, R., Dietel, M., Schadendorf, D. and Sinha P. (2001) Enhanced expression of human ABC-transporter tap is associated with cellular resistance to mitoxantrone. FEBS Lett. 503, 179-184.
80. Ruetz, S. and Gros, P. (1994) Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell 77, 1071-1081.
81. Childs, S., Yeh, R. L., Hui, D. and Ling, V. (1998) Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein. Cancer Res. 58, 4160-4167.
82. Gerloff, T., Stieger, B., Hagenbuch, B., Madon, J., Landmann, L., Roth, J., Hofmann, A. F. and Meier, P. J. (1998) The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J. Biol. Chem. 273, 10046-10050.
83. Yasui, K., Mihara, S., Zhao, C., Okamoto, H., Saito-Ohara, F., Tomida, A., Funato, T., Yokomizo, A., Naito, S., Imoto, I., Tsuruo, T. and Inazawa, J. (2004) Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res. 64, 1403-1410.
84. Paterson, J. K., Shukla, S., Black, C. M., Tachiwada, T., Garfield, S., Wincovitch, S., Ernst, D. N., Agadir, A., Li, X., Ambudkar, S. V., Szakacs, G., Akiyama, S. and Gottesman, M. M. (2007) Human ABCB6 localizes to both the outer mitochondrial membrane and the plasma membrane. Biochemistry 46, 9443-9452.
85. Zollner, G., Wagner, M., Fickert, P., Silbert, D., Fuchsbichler, A., Zatloukal, K., Denk, H. and Trauner, M. (2005) Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int. 25, 367-379.
86. Efferth, T., Gillet, J. P., Sauerbrey, A., Zintl, F., Bertholet, V., de Longueville, F., Remacle, J. and Steinbach, D. (2006) Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. Mol. Cancer Ther. 5, 1986-1994.
87. Park, S., Shimizu, C., Shimoyama, T., Takeda, M., Ando, M., Kohno, T., Katsumata, N., Kang, Y. K., Nishio, K. and Fujiwara, Y. (2006) Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res. Treat. 99, 9-17.
88. Chen, K. G., Szak-cs, G., Annereau, J. P., Rouzaud, F., Liang, X. J., Valencia, J. C., Nagineni, C. N., Hooks, J. J., Hearing, V. J. and Gottesman, M. M. (2005) Principal expression of two mRNA isoforms (ABCB 5alpha and ABCB 5beta) of the ATP-binding cassette transporter gene ABCB 5 inmelanoma cells and melanocytes. Pigment Cell Res. 18, 102-112.
89. Frank, N. Y., Margaryan, A., Huang, Y., Schatton, T., Waaga-Gasser, A. M., Gasser, M., Sayegh, M. H., Sadee, W. and Frank, M. H. (2005) ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 65, 4320-4333.
90. Schatton, T., Murphy, G. F., Frank, N. Y., Yamaura, K., Waaga-Gasser, A. M., Gasser, M., Zhan, Q., Jordan, S., Duncan, L. M., Weishaupt, C., Fuhlbrigge, R. C., Kupper, T. S., Sayegh, M. H. and Frank, M. H. (2008) Identification of cells initiating human melanomas. Nature 451, 345-349.
91. Nieth, C. and Lage, H. (2005) Induction of the ABC-transporters Mdr1/P-gp (Abcb1), mrpl (Abcc1), and bcrp (Abcg2) during establishment of multidrug resistance following exposure to mitoxantrone. J. Chemother. 17, 215-223.
92. Gillet, J. P., Efferth, T., Steinbach, D., Hamels, J., de Longueville, F., Bertholet, V. and Remacle, J. (2004) Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res. 64, 8987-8993.
93. Huang, Y., Anderle, P., Bussey, K. J., Barbacioru, C., Shankavaram, U., Dai, Z., Reinhold, W. C., Papp, A., Weinstein, J. N. and Sadée, W. (2004) Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res. 64, 4294-4301.
94. Szakács, G., Annereau, J. P., Lababidi, S., Shankavaram, U., Arciello, A., Bussey, K. J., Reinhold, W., Guo, Y., Kruh, G. D., Reimers, M., Weinstein, J. N. and Gottesman, M. M. (2004) Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6, 129-137.
95. Liu, Y., Peng, H. and Zhang, J. T. (2005) Expression profiling of ABC transporters in a drug-resistant breast cancer cell line using AmpArray. Mol. Pharmacol. 68, 430-438.
96. Efferth, T., Gillet, J. P., Sauerbrey, A., Zintl, F., Bertholet, V., de Longueville, F., Remacle, J. and Steinbach, D. (2006) Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. Mol. Cancer Ther. 5, 1986-1994.
97. Gillet, J. P., Schneider, J., Bertholet, V., de Longueville, F., Remacle, J. and Efferth, T. (2006) Microarray Expression Profiling of ABC Transporters in Human Breast Cancer. Cancer Genomics Proteomics 3, 97-106.
98. Awasthi, S., Singhal, S. S., Sharma, R., Zimniak, P. and Awasthi, Y. C. (2003) Transport of glutathione conjugates and chemotherapeutic drugs by RLIP76 (RALBP1): a novel link between G-protein and tyrosine kinase signaling and drug resistance. Int. J. Cancer 106, 635-646.
99. Awasthi, Y. C., Sharma, R., Yadav, S., Dwivedi, S., Sharma, A. and Awasthi, S. (2007) The non-ABC drug transporter RLIP76 (RALBP-1) plays a major role in the mechanisms of drug resistance. Curr. Drug Metab. 8, 315-323.
100. Singhal, S. S., Singhal, J., Nair, M. P., Lacko, A. G., Awasthi, Y. C. and Awasthi, S. (2007) Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int. J. Oncol. 30, 717-725.
101. Hudson, M. E., Pozdnyakova, I., Haines, K., Mor, G. and Snyder, M. (2007) Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc. Natl. Acad. Sci. USA 104, 17494-17499.
102. Safaei, R. (2006) Role of copper transporters in the uptake and efflux of platinum containing drugs. Cancer Lett. 234, 34-39.
103. Kuo, M. T., Chen, H. H., Song, I. S., Savaraj, N. and Ishikawa T. (2007) The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev. 26, 71-83.
104. Kanzaki, A., Toi, M., Neamati, N., Miyashita, H., Oubu, M., Nakayama, K., Bando, H., Ogawa, K., Mutoh, M., Mori, S., Terada, K., Sugiyama, T., Fukumoto, M. and Takebayashi, Y. (2002) Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma. Jpn. J. Cancer Res. 93, 70-77.
105. Nakayama, K., Kanzaki, A., Terada, K., Mutoh, M., Ogawa, K., Sugiyama, T., Takenoshita, S., Itoh, K., Yaegashi, N., Miyazaki, K., Neamati, N. and Takebayashi, Y. (2004) Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy. Clin. Cancer Res. 10, 2804-2811.
106. Safaei, R., Holzer, A. K., Katano, K., Samimi, G. and Howell, S. B. (2004) The role of copper transporters in the development of resistance to Pt drugs. J. Inorg. Biochem. 98, 1607-1613.
107. Okada, H. and Mak, T. W. (2004) Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer 4, 592-603.
108. Brown, J. M. and Attardi, L. D. (2005)The role of apoptosis in cancer development and treatment response. Nat. Rev. Cancer 5, 231-237.
109. Hengartner, M. O. (2000) The biochemistry of apoptosis. Nature 407, 770-776.
110. Viktorsson, K., Lewensohn, R. and Zhivotovsky, B. (2005) Apoptotic pathways and therapy resistance in human malignancies. Adv. Cancer Res. 94, 143-196.
111. Johnstone, R. W., Ruefli, A. A. and Lowe, S. W. (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153-164.
112. Mashima, T. and Tsuruo, T. (2005) Defects of the apoptotic pathway as therapeutic target against cancer. Drug Resist. Updat. 8, 339-343.
113. Danial, N. N. (2007) BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin. Cancer Res. 13, 7254-7263.
114. Youle, R. J. and Strasser, A. (2008)The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9, 47-59.
115. Buchholz, T. A., Davis, D. W., McConkey, D. J., Symmans, W. F., Valero, V., Jhingran, A., Tucker, S. L., Pusztai, L., Cristofanilli, M., Esteva, F. J., Hortobagyi, G. N. and Sahin, A. A. (2003) Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J. 9, 33-41.
116. Kupryjańczyk, J., Szymańska, T., Madry, R., Timorek, A., Stelmachw, J., Karpińska, G., Rembiszewska, A., Ziółkowska, I., Kraszewska, E., Debniak, J., Emerich, J., Ułańska, M., Płuzańska, A., Jedryka, M., Goluda, M., Chudecka-Głaz, A., Rzepka-Grska, I., Klimek, M., Urbański, K., Breborowicz, J., Zieliński, J. and Markowska, J. Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. Br. J. Cancer 88, 848-854.
117. Khor, L. Y., Moughan, J., Al-Saleem, T., Hammond, E. H., Venkatesan, V., Rosenthal, S. A., Ritter, M. A., Sandler, H. M., Hanks, G. E., Shipley, W. U. and Pollack, A. (2007) Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02. Clin. Cancer Res. 13, 3585-3590.
118. Harada, T., Ogura, S., Yamazaki, K., Kinoshita, I., Itoh, T., Isobe, H., Yamashiro, K., Dosaka-Akita, H. and Nishimura, M. (2003) Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers. Cancer Sci. 94, 394-399.
119. Krug, L. M., Miller, V. A., Filippa, D. A., Venkatraman, E., Ng, K. K. and Kris MG. (2003) Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine. Lung Cancer 39, 139-143.
120. Saito, T., Takehara, M., Tanaka, R., Lee, R., Horie, M., Wataba, K., Ito, E. and Kudo, R. (2004) Correlation between responsiveness of neoadjuvant chemotherapy and apoptosis-associated proteins for cervical adenocarcinoma. Gynecol. Oncol. 92, 284-292.
121. Johnstone, R. W., Cretney, E. and Smyth, M. J. (1999) Pglycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 93, 1075-1085.
122. Kojima, H., Endo, K., Moriyama, H., Tanaka, Y., Alnemri, E. S., Slapak, C. A., Teicher, B., Kufe, D. and Datta, R. (1998) Abrogation of mitochondrial cytochrome c release and caspase-3 activation in acquired multidrug resistance. J. Biol. Chem. 273, 16647-16650.
123. Evseenko, D. A., Murthi, P., Paxton, J. W., Reid, G., Emerald, B. S., Mohankumar, K. M., Lobie, P. E., Brennecke, S. P., Kalionis, B. and Keelan, J. A. (2007) The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction. FASEB J. 21, 3592-3605.
124. de Groot, D. J., van der Deen, M., Le, T. K., Regeling, A., de Jong, S. and de Vries, E. G. (2007) Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicinresistant small-cell lung cancer cells overexpressing MRP1. Br. J. Cancer 97, 1077-1083.
125. Ferreira, C. G., Tolis, C. and Giaccone, G. (1999) p53 and chemosensitivity. Ann. Oncol. 10, 1011-1021.
126. Lage, H. and Dietel, M. (1999) Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J. Cancer Res. Clin. Oncol. 125, 156-165.
127. Kaina, B. and Christmann, M. (2002) DNA repair in resistance to alkylating anticancer drugs. Int. J. Clin. Pharmacol. Ther. 40, 354-367.
128. Bradbury, P. A. and Middleton, M. R. (2004) DNA repair pathways in drug resistance in melanoma. Anticancer Drugs 15, 421-426.
129. Gerson, S. L. (2004) MGMT: its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer 4, 296-307.
130. Fuqua, S. A., Oesterreich, S., Hilsenbeck, S. G., Von Hoff, D. D., Eckardt, J. and Osborne, C. K. (1994) Heat shock proteins and drug resistance. Breast Cancer Res. Treat. 32, 67-71.
131. Hegi, M. E., Diserens, A. C., Gorlia, T., Hamou, M. F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., Bromberg, J. E., Hau, P., Mirimanoff, R. O., Cairncross, J. G., Janzer, R. C. and Stupp, R. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997-1003.
132. Rau, B., Sturm, I., Lage, H., Berger, S., Schneider, U., Hauptmann, S., Wust, P., Riess, H., Schlag, P. M., Dçrken, B. and Daniel, P. T. (2003) Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J. Clin. Oncol. 21, 3391-3401.
133. Cahill, D. P., Levine, K. K., Betensky, R. A., Codd, P. J., Romany, C. A., Reavie, L. B., Batchelor, T. T., Futreal, P. A., Stratton, M. R., Curry, W. T., Iafrate, A. J. and Louis, D. N. (2007) Loss of themismatch rtepair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin. Cancer Res. 13, 2038-2045.
134. Idikio, H. A. (2001) Expression of DNA mismatch repair proteins hMSH2 and hMLH1 and the cyclin G1 inhibitor, p21(waf1/cip1) in pediatric tumors: correlation with response to therapy. Oncol. Rep. 8, 965-971.
135. Mackay, H. J., Cameron, D., Rahilly, M., Mackean, M. J., Paul, J., Kaye, S. B. and Brown R. (2003) Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J. Clin. Oncol. 18, 87-93.
136. Scartozzi, M., De Nictolis, M., Galizia, E., Carassai, P., Bianchi, F., Berardi, R., Gesuita, R., Piga, A., Cellerino, R. and Porfiri, E. (2003) Loss of hMLH1 expression correlates with improved survival in stage III-IVovarian cancer patients. Eur. J. Cancer 39, 1144-1149.
137. Rosell, R., Mendez, P., Isla, D. and Taron, M. (2007) Platinum resistance related to a functional NER pathway. J. Thorac. Oncol. 2, 1063-1066.
138. Xu, Z., Chen, Z. P., Malapetsa, A., Alaoui-Jamali, M., Bergeron, J., Monks, A., Myers, T. G., Mohr, G., Sausville, E. A., Scudiero, D. A., Aloyz, R. and Panasci, L. C. (2002) DNArepair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anticancer Drugs 13, 511-519.
139. Melton, D. W., Ketchen, A. M., Núñez, F., Bonatti-Abbondandolo, S., Abbondandolo, A., Squires, S. and Johnson R. T. (1998) Cells from ERCC1-deficient mice show increased genome instability and a reduced frequency of S-phase-dependent illegitimate chromosome exchange but a normal frequency of homologous recombination. J. Cell Sci. 111, 395-404.
140. Youn, C. K., Kim, M. H., Cho, H. J., Kim, H. B., Chang, I. Y., Chung, M. H. and You, H. J. (2004) Oncogenic H-Ras upregulates expression of ERCC1 to protect cells from platinum-based anticancer agents. Cancer Res. 64, 4849-4857.
141. Metzger, R., Leichman, C. G., Danenberg, K. D., Danenberg, P. V., Lenz, H. J., Hayashi, K., Groshen, S., Salonga, D., Cohen, H., Laine, L., Crookes, P., Silberman, H., Baranda, J., Konda, B. and Leichman, L. (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol. 16, 309-316.
142. Shirota, Y., Stoehlmacher, J., Brabender, J., Xiong, Y. P., Uetake, H., Danenberg, K. D., Groshen, S., Tsao-Wei, D. D., Danenberg, P. V. and Lenz H. J. (2001) ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 19, 4298-4304.
143. Lord, R. V., Brabender, J., Gandara, D., Alberola, V., Camps, C., Domine, M., Cardenal, F., S-nchez, J. M., Gumerlock, P. H., Tarón, M., Sánchez, J. J., Danenberg, K. D., Danenberg, P. V. and Rosell, R. (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 8, 2286-2291.
144. Trivedi, R. N., Almeida, K. H., Fornsaglio, J. L., Schamus, S. and Sobol, R. W. (2005) The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res. 65, 6394-6400.
145. Britten, R. A., Kuny, S. and Perdue, S. (1999) Modification of non-conservative double-strand break (DSB) rejoining activity after the induction of cisplatin resistance in human tumour cells. Br. J. Cancer 79, 843-849.
146. Kellner, U., Sehested, M., Jensen, P. B., Gieseler, F. and Rudolph, P. (2002) Culprit and victim - DNA topoisomerase II. Lancet Oncol. 3, 235-243.
147. Montecucco, A. and Biamonti, G. (2007) Cellular response to etoposide treatment. Cancer Lett. 252, 9-18.
148. Danks, M. K., Schmidt, C. A., Cirtain, M. C., Suttle, D. P. and Beck, W. T. (1988) Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27, 8861-8869.
149. Coon, J. S., Marcus, E., Gupta-Burt, S., Seelig, S., Jacobson, K., Chen, S., Renta, V., Fronda, G. and Preisler H. D. (2002) Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res. 8, 1061-1067.
150. MacGrogan, G., Rudolph, P., Mascarel Id, I., Mauriac, L., Durand, M., Avril, A., Dilhuydy, J. M., Robert, J., Mathoulin-Pélissier, S., Picot, V., Floquet, A., Sierankowski, G. and Coindre, J. M. (2003) DNA topoisomerase IIalpha expression and the response to primary chemotherapy in breast cancer. Br. J. Cancer 89, 666-671.
151. Scandinavian Breast Group Trial 9401, Tanner, M., Isola, J., Wiklund, T., Erikstein, B., Kellokumpu-Lehtinen, P., Malmström, P., Wilking, N., Nilsson, J. and Bergh, J. (2006) Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J. Clin. Oncol. 24, 2428-2436.
152. Dingemans, A. M., Witlox, M. A., Stallaert, R. A., van der Valk, P., Postmus, P. E. and Giaccone, G. (1999) Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin. Cancer Res. 5, 2048-2058.
153. Dingemans, A. C., van Ark-Otte, J., Span, S., Scagliotti, G. V., van der Valk, P., Postmus, P. E. and Giaccone, G. (2001) Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer. Lung Cancer 32, 117-128.
154. Townsend, D. M. and Tew, K. D. (2003) The role of glutathione-S- transferase in anti-cancer drug resistance. Oncogene 22, 7369-7375.
155. Kelley, S. L., Basu, A., Teicher, B. A., Hacker, M. P., Hamer, D. H. and Lazo, J. S. (1988) Overexpression of metallothionein confers resistance to anticancer drugs. Science 241, 1813-1815.
156. McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., Jain, V., Ho, A. D., Lister, J., Wey, K., Shen, D. and Dallaire, B. K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825-2833.
157. Bonavida, B. (2007) Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 26, 3629-3636.
158. Deininger, M., Buchdunger, E. and Druker, B. J. (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105, 2640-2653.
159. Mahon, F. X., Belloc, F., Lagarde, V., Chollet, C., Moreau-Gaudry, F., Reiffers, J., Goldman, J. M. and Melo, J. V. (2003) MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101, 2368-2373.
160. Burger, H., van Tol, H., Boersma, A. W., Brok, M., Wiemer, E. A., Stoter, G., Nooter, K. (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104, 2940-2942.
161. Mukai, M., Che, X. F., Furukawa, T., Sumizawa, T., Aoki, S., Ren, X. Q., Haraguchi, M., Sugimoto, Y., Kobayashi, M., Takamatsu, H. and Akiyama, S. (2003) Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells. Cancer Sci. 94, 557-563.
162. Houghton, P. J., Germain, G. S., Harwood , F. C., Schuetz, J. D., Stewart, C. F., Buchdunger, E. and Traxler, P. (2004) Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res. 64, 2333-2337.
163. Goldman, J. M. (2007) How I treat chronic myeloid leukemia in the imatinib era. Blood 110, 2828-2837.
164. Fiala, S. (1968) The cancer cell as a stem cell unable to differentiate. A theory of carcinogenesis. Neoplasma 15, 607-622.
165. Clarke, M. F., Dick, J. E., Dirks, P. B., Eaves, C. J., Jamieson, C. H., Jones, D. L., Visvader, J., Weissman, I. L. and Wahl, G. M. (2006) Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66, 9339-9344.
166. Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A. and Dick, J. E. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645-648.
167. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. and Clarke, M. F. (2003) Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100, 3983-3988.
168. Hemmati, H. D., Nakano, I., Lazareff, J. A., Masterman-Smith, M., Geschwind, D. H., Bronner-Fraser, M. and Kornblum, H. I. (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. USA 100, 15178-15183.
169. Hirschmann-Jax, C., Foster, A. E., Wulf, G. G., Nuchtern, J. G., Jax, T. W., Gobel, U., Goodell, M. A. and Brenner, M. K. (2004) A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. USA 101, 14228-14233.
170. Dean, M., Fojo, T. and Bates, S. (2005) Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284.
171. Lou, H. and Dean, M. (2007) Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 26, 1357-1360.
172. Hirschmann-Jax, C., Foster, A. E., Wulf, G. G., Nuchtern, J. G., Jax, T. W., Gobel, U., Goodell, M. A. and Brenner, M. K. (2004) A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. USA 101, 14228-14233.
173. Ho, M. M., Ng, A. V., Lam, S. and Hung, J. Y. (2007) Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 67, 4827-4833.
174. Zabierowski, S. E. and Herlyn, M. (2008) Learning the ABCs of melanoma-initiating cells. Cancer Cell 13, 185-187.
175. Zhou, J., Wang, C. Y., Liu, T., Wu, B., Zhou, F., Xiong, J. X., Wu, H. S., Tao, J., Zhao, G., Yang, M. and Gou, S. M. (2008) Persistence of side population cells with high drug efflux capacity in pancreatic cancer. World J. Gastroenterol. 14, 925-930.
176. Nowell, P. C. (1976) The clonal evolution of tumor cell populations. Science 194, 23-28.
177. Schwartz, G. K. and Shah, M. A. (2005) Targeting the cell cycle: a new approach to cancer therapy. J. Clin. Oncol. 23, 9408-9421.
178. Nevins J. R. and Potti, A. (2007) Mining gene expression profiles: expression signatures as cancer phenotypes. Nat. Rev. Genet. 8, 601-609.
179. den Boer, M. L. and Pieters, R. (2007) Microarray-based identification of new targets for specific therapies in pediatric leukemia. Curr. Drug Targets 8, 761-764.
180. Györffy, B. and Lage, H. (2007) A Web-based data warehouse on gene expression in human malignant melanoma. J. Invest. Dermatol. 127, 394-399.
181. Minna, J. D., Girard, L. and Xie, Y. (2007) Tumor mRNA expression profiles predict responses to chemotherapy J. Clin. Oncol. 25, 4329-4336.
182. Györffy, B., Dietel, M., Fekete, T. and Lage, H. (2008) A snapshot of microarray-generated gene expression signatures associated with ovarian carcinoma. Int. J. Gynecol. Cancer [Epub ahead of print]
183. Lage, H. (2004) Proteomics in cancer cell research: an analysis of therapy resistance. Pathol. Res. Pract. 200, 105-117.
184. Rigetti, P. G., Castagna, A., Antonioli, P., Lecconi, D., Campostrini, N. and Rigetti, S. C. (2005) Proteomic approaches for studying chemoresistance in cancer. Expert Rev. Proteomics 2, 215-228.
185. Sagynaliev, E., Steinert, R., Nestler, G., Lippert, H., Knoch, M. and Reymond, M. A. (2005) Web-based data warehouse on gene expression in human colorectal cancer. Proteomics 5, 3066-3078.
186. Ma, Y., Ding, Z., Qian, Y., Shi, X., Castranova, V., Harner, E. J. and Guo, L. (2006) Predicting cancer drug response by proteomic profiling. Clin. Cancer Res. 12, 4583-4589.
187. Zhang, J. T. and Liu, Y. (2007) Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment. Cancer Treat. Rev. 33, 741-756.
188. van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., Schreiber, G. J., Kerkhoven, R. M., Roberts, C., Linsley, P. S., Bernards, R. and Friend, S. H. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536.
189. Thuerigen, O., Schneeweiss, A., Toedt, G., Warnat, P., Hahn, M., Kramer, H., Brors, B., Rudlowski, C., Benner, A., Schuetz, F., Tews, B., Eils, R., Sinn, H. P., Sohn, C. and Lichter, P. (2006) Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J. Clin. Oncol. 24, 1839-1845.
190. Del Rio, M., Molina, F., Bascoul-Mollevi, C., Copois, V., Bibeau, F., Chalbos, P., Bareil, C., Kramar, A., Salvetat, N., Fraslon, C., Conseiller, E., Granci, V., Leblanc, B., Pau, B., Martineau, P. and Ychou, M. (2007) Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J. Clin. Oncol. 25, 773-780.
191. Dressman, H. K., Berchuck, A., Chan, G., Zhai, J., Bild, A., Sayer, R., Cragun, J., Clarke, J., Whitaker, R. S., Li, L., Gray, J., Marks, J., Ginsburg, G. S., Potti, A., West, M., Nevins, J. R. and Lancaster, J. M. (2007) An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J. Clin. Oncol. 25, 517-525.
192. Stein, U. and Walther, W. (2006) Reversal of ABC transporter-dependent multidrug resistance in cancer, a realistic option? Am. J. Cancer 5, 285-297.
193. Thomas, H. and Coley, H. M. (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10, 159-165.
194. Trompier, D., Chang, X. B., Barattin, R., du Moulinet d Hardemare, A., Di Pietro, A. and Baubichon-Cortay, H. (2004) Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1. Cancer Res. 64, 4950-4956.
195. Laberge, R. M., Karwatsky, J., Lincoln, M. C., Leimanis, M. L. and Georges, E. (2007) Modulation of GSH levels in ABCC1 expressing tumor cells triggers apoptosis through oxidative stress. Biochem. Pharmacol. 73, 1727-1737.
196. Perrotton T, Trompier D, Chang XB, Di Pietro A, Baubichon-Cortay H. (2007) (R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1. J. Biol. Chem. 282, 31542-31548.
197. Greenberg, P. L., Lee, S. J., Advani, R., Tallman, M. S., Sikic, B. I., Letendre, L., Dugan, K., Lum, B., Chin, D. L., Dewald, G., Paietta, E., Bennett, J. M. and Rowe, J. M. (2004) Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J. Clin. Oncol. 22, 1078-1086.
198. van der Holt, B., Löwenberg, B., Burnett, A. K., Knauf, W. U., Shepherd, J., Piccaluga, P. P., Ossenkoppele, G. J., Verhoef, G. E., Ferrant, A., Crump, M., Selleslag, D., Theobald, M., Fey, M. F., Vellenga, E., Dugan, M. and Sonneveld, P. (2005) The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106, 2646-2654.
199. Friedenberg, W. R., Rue, M., Blood, E. A., Dalton, W. S., Shustik, C., Larson, R. A., Sonneveld, P. and Greipp, P. R. (2006) Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer 106, 830-838.
200. Fracasso, P. M., Goldstein, L. J., de Alwis, D. P., Rader, J. S., Arquette, M. A., Goodner, S. A., Wright, L. P., Fears, C. L., Gazak, R. J., Andre, V. A., Burgess, M. F., Slapak, C. A. and Schellens, J. H. (2004) Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin. Cancer Res. 10, 7220-7228.
201. Sandler, A., Gordon, M., De Alwis, D. P., Pouliquen, I., Green, L., Marder, P., Chaudhary, A., Fife, K., Battiato, L., Sweeney, C., Jordan, C., Burgess, M. and Slapak, C. A. (2004) A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin. Cancer Res. 10, 3265-3272.
202. Morschhauser, F., Zinzani, P. L., Burgess, M., Sloots, L., Bouafia, F. and Dumontet, C. (2007) Phase I/II trial of a Pglycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin s lymphoma. Leuk. Lymphoma 48, 708-715.
203. Mechetner, E. B. and Roninson, I. B. (1992) Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc. Natl. Acad. Sci. USA 89, 5824-5828.
204. Lage, H. (2006) MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. Curr. Drug Targets 7, 813-821.
205. Stein, U., Walther, W., Stege, A., Kaszubiak, A., Fichtner, I. and Lage, H. (2008) Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA. Mol. Ther. 16, 178-186.
206. Beck, W. T., Grogan, T. M., Willman, C. L., Cordon-Cardo, C., Parham, D. M., Kuttesch, J. F., Andreeff, M., Bates, S. E., Berard, C. W., Boyett, J. M., Brophy, N. A., Broxterman, H. J., Chan, H. S., Dalton, W. S., Dietel, M., Fojo, A. T., Gascoyne, R. D., Head, D., Houghton, P. J., Srivastava, D. K., Lehnert, M., Leith, C. P., Paietta, E., Pavelic, Z. P. and Weinstein, R. (1996) Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 56, 3010-3020.
207. Vulevic, B., Chen, Z., Boyd, J. T., Davis, W.Jr., Walsh, E. S., Belinsky, M. G. and Tew, K. D. (2001) Cloning and characterization of human adenosine 5′-triphosphate-binding cassette, sub-family A, transporter 2 (ABCA2). Cancer Res. 61, 3339-3347.
208. Boonstra, R., Timmer-Bosscha, H., van Echten-Arends, J., van der Kolk, D. M., van den Berg, A., de Jong, B., Tew, K. D., Poppema, S. and de Vries, E. G. (2004) Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation. Br. J. Cancer 90, 2411-2417.
209. Mack, J. T., Townsend, D. M., Beljanski, V. and Tew, K. D. (2007) The ABCA2 transporter: intracellular roles in trafficking and metabolism of LDL-derived cholesterol and sterol-related compounds. Curr. Drug Metab. 8, 47-57.
210. Ueda, K., Yoshida, A. and Amachi, T. (1999) Recent progress in P-glycoprotein research. Anticancer Drug Des. 14, 115-121.
211. Borst, P., Evers, R., Kool, M. and Wijnholds, J. (2000) A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92, 1295-1302.
212. König, J., Nies, A. T., Cui, Y., Leier, I. and Keppler, D. (1999) Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta 1461, 377-394.
213. Cui, Y., König, J., Buchholz, J. K., Spring, H., Leier, I. and Keppler, D. (1999) Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. 55, 929-937.
214. Kool, M., van der Linden, M., de Haas, M., Scheffer, G. L., de Vree, J. M., Smith, A. J., Jansen, G., Peters, G. J., Ponne, N., Scheper, R. J., Elferink, R. P., Baas, F. and Borst, P. (1999) MRP3, an organic anion transporter able to transport anticancer drugs. Proc. Natl. Acad. Sci. USA 96, 6914-6919.
215. Zeng, H., Bain, L. J., Belinsky, M. G. and Kruh, G. D. (1999) Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res. 59, 5964-5967.
216. de Jong, M. C., Slootstra, J. W., Scheffer, G. L., Schroeijers, A. B., Puijk, W. C., Dinkelberg, R., Kool, M., Broxterman, H. J., Meloen, R. H. and Scheper, R. J. (2001) Peptide transport by the multidrug resistance protein MRP1. Cancer Res. 61, 2552-2557.
217. Schuetz, J. D., Connelly, M. C., Sun, D., Paibir, S. G., Flynn, P. M., Srinivas, R. V., Kumar, A. and Fridland, A. (1999) MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat. Med. 5, 1048-1051.
218. Chen, Z. S., Lee, K. and Kruh, G. D. (2001) Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J. Biol. Chem. 276, 33747-33754.
219. Chen, Z. S., Lee, K., Walther, S., Raftogianis, R. B., Kuwano, M., Zeng, H. and Kruh, G. D. (2002) Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 62, 3144-3150.
220. Wijnholds, J., Mol, C. A., van Deemter, L., de Haas, M., Scheffer, G. L., Baas, F., Beijnen, J. H., Scheper, R. J., Hatse, S., De Clercq, E., Balzarini, J. and Borst, P. (2000) Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc. Natl. Acad. Sci. USA 97, 7476-7481.
221. Jedlitschky, G., Burchell, B. and Keppler, D. (2000) The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J. Biol. Chem. 275, 30069-30074.
222. Doyle, L. A. and Ross, D. D. (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22, 7340-7358.